- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Transthyretin amyloid cardiomyopathy (ATTR-CM)
- Meeting Date: July 2026
Vutrisiran – July 2026
- Injection 25 mg (as sodium) in 0.5 mL pre-filled syringe
Public Summary Documents
Last updated
13 November 2026
